Serial echocardiographs are used to track the progressive effectiveness of the therapy, though a rebound in tumour size may occur after rapid discontinuation of mTOR inhibitors, necessitating close follow-up, even after complete regression of cardiac lesions [48]. Here, MTOR is linked to neoplasm.